Sickle Cell Disease Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

Sickle Cell Disease pipeline constitutes 40+ key companies continuously working towards developing 50+ Sickle Cell Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Sickle Cell Disease Overview
Sickle Cell Disease is a group of inherited red blood cell disorders that affects hemoglobin, the protein that carries oxygen through the body. Sickle cells are destroyed rapidly in the bodies of people with the disease, causing anemia which is why it is commonly known as sickle cell anemia. The sickle cells also block blood flow through vessels, resulting in lung tissue damage that causes acute chest syndrome, pain episodes, stroke, priapism, and damage to the spleen, kidneys, and liver.

Sickle Cell Disease Treatments might include medications to reduce pain and prevent complications, blood transfusions, as well as a bone marrow transplant

"Sickle Cell Disease Pipeline Insight, 2022" report by DelveInsight, outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sickle Cell Disease Market.

The Sickle Cell Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sickle Cell Disease Pipeline Report https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Companies across the globe are diligently working toward developing novel Sickle Cell Disease treatment therapies with a considerable amount of success over the years. Sickle Cell Disease Key players such as - Sana Biotechnology, Cellectis, Pfizer, CSL Behring, Global Blood Therapeutics Inc., Novartis, Graphite Bio, Aruvant Sciences, Forma therapeutics, Agios Pharmaceuticals, Vertex Pharmaceuticals, and others, are developing therapies for the Sickle Cell Disease treatment

Sickle Cell Disease Emerging therapies such as - SG418, TALGlobin01, PF-07209326, Pfizer, CSL889, CSL Behring, GBT021601, OTQ923, GPH101, ARU-1801, Etavopivat, Mitapivat, Inclacumab, CTX001, and others are expected to have a significant impact on the Sickle Cell Disease market in the coming years

In September 2020, CRISPR Therapeutics and Vertex Pharmaceuticals announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, exvivo CRISPR/Cas9 gene-edited therapy for the treatment of severe sickle cell disease (SCD)

In May 2020, US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX001, an investigational, autologous, gene-edited hematopoietic stem cell therapy for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)

In January 2019, the United States FDA granted Fast Track Designation for CTX001 for the treatment of sickle cell disease (SCD). In January 2020, European Commission granted Orphan Drug Designation for CTX001 for sickle cell disease treatment

In October 2018, CRISPR and Vertex announced the FDA acceptance of the Investigational New Drug application (IND) for CTX001 for the treatment of sickle cell disease

Sickle Cell Disease Pipeline Therapeutics Assessment
Sickle Cell Disease Assessment by Product Type
Sickle Cell Disease By Stage and Product Type
Sickle Cell Disease Assessment by Route of Administration
Sickle Cell Disease By Stage and Route of Administration
Sickle Cell Disease Assessment by Molecule Type
Sickle Cell Disease by Stage and Molecule Type

DelveInsight's Sickle Cell Disease Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Emerging Sickle Cell Disease Drugs Under Different Phases of Clinical Development Include:
SG418: Sana Biotechnology
TALGlobin01: Cellectis
PF-07209326: Pfizer
CSL889: CSL Behring
GBT021601: Global Blood Therapeutics, Inc.
OTQ923: Novartis
GPH101: Graphite Bio
ARU-1801: Aruvant Sciences
Etavopivat: Forma therapeutics
Mitapivat: Agios Pharmaceuticals
Inclacumab: Global Blood Therapeutics, Inc.
CTX001: Vertex Pharmaceuticals

Further Sickle Cell Disease product details are provided in the report. Download the Sickle Cell Disease pipeline report to learn more about the emerging Sickle Cell Disease therapies at: https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sickle Cell Disease Pipeline Analysis:
The Sickle Cell Disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the Sickle Cell Disease treatment with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sickle Cell Disease Treatment.

Sickle Cell Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Sickle Cell Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sickle Cell Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Sickle Cell Disease Pipeline Market Drivers

Increasing Sickle Cell Disease prevalence
Rising demand for better treatment
Growing health awareness

Sickle Cell Disease Pipeline Market Barriers
High cost of Sickle Cell Disease treatment
Lack of FDA approved treatment

Get a Free Sample PDF Report to know more about Sickle Cell Disease Pipeline Assessment- https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Sickle Cell Disease Pipeline Drug Insight
Coverage: Global
Key Sickle Cell Disease Companies: Sana Biotechnology, Cellectis, Pfizer , CSL Behring, Global Blood Therapeutics Inc., Novartis, Graphite Bio, Aruvant Sciences, Forma therapeutics, Agios Pharmaceuticals, Vertex Pharmaceuticals, and others
Key Sickle Cell Disease Therapies: SG418, TALGlobin01, PF-07209326, Pfizer, CSL889, CSL Behring, GBT021601, OTQ923, GPH101, ARU-1801, Etavopivat, Mitapivat, Inclacumab, CTX001, and others
Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies
Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers
Request for Sample PDF Report for Sickle Cell Disease Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Sickle Cell Disease Report Introduction
2 Sickle Cell Disease Executive Summary
3 Sickle Cell Disease Overview
4 Sickle Cell Disease- Analytical Perspective In-depth Commercial Assessment
5 Sickle Cell Disease Pipeline Therapeutics
6 Sickle Cell Disease Late Stage Products (Phase II/III)
7 Sickle Cell Disease Mid Stage Products (Phase II)
8 Sickle Cell Disease Early Stage Products (Phase I)
9 Sickle Cell Disease Preclinical Stage Products
10 Sickle Cell Disease Therapeutics Assessment
11 Sickle Cell Disease Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Sickle Cell Disease Key Companies
14 Sickle Cell Disease Key Products
15 Sickle Cell Disease Unmet Needs
16 Sickle Cell Disease Market Drivers and Barriers
17 Sickle Cell Disease Future Perspectives and Conclusion
18 Sickle Cell Disease Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Sickle Cell Disease drugs and therapies- https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Sickle Cell Disease Market https://www.delveinsight.com/report-store/sickle-cell-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Sickle Cell Disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom)

Sickle Cell Disease Epidemiology https://www.delveinsight.com/report-store/sickle-cell-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Sickle Cell Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Trending Reports:

Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.


Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.


Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027

To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.